Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6194489 | Urologic Oncology: Seminars and Original Investigations | 2014 | 12 Pages |
Abstract
Temsirolimus makes a moderate contribution in terms of cell proliferation, apoptosis, and autophagy. However, it does potentiate the activity of gemcitabine and particularly cisplatin. Therefore, cisplatin- or gemcitabine-based chemotherapy regimen used in combination with temsirolimus to treat bladder cancer represents a novel and valuable treatment option, which should be tested for future studies in urinary bladder xenograft models.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Rosário M.Sc., Regina M.Sc., Rita Ph.D., Carlos Ph.D., Aura Ph.D., VÃtor M.D., Paula Ph.D., Lúcio M.D., Ph.D.,